FirsthandHealth
medRxiv PreprintsInternational16 November 2026

Sublingual Buprenorphine Is Associated with Increased Caries Experience and Altered Oral Microbial and Salivary Risk Factors

This is an official announcement record

Firsthand records what medRxiv Preprints announced and links to the original. The wording below is theirs, not ours.

Background: Sublingual buprenorphine (SLB) is commonly prescribed to treat opioid use disorder. Pharmacoepidemiologic studies suggest an association between SLB and severe dental caries, yet clinical investigations are lacking. Objective: To assess caries experience and caries-related risk factors among patients taking SLB. Methods: This pilot cross-sectional study enrolled 11 subjects taking SLB films, 10 taking SLB tablets, and 10 age- and sex-matched controls. Demographic, medical, dental, and behavioral data were collected. Caries examinations were performed. Salivary pH, buffering capacit
Source: medRxiv Preprints
Read the official announcement

Opens www.medrxiv.org

More from medRxiv Preprints

This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.